NEW YORK (360Dx) – The US Food and Drug Administration said today that Laboratory Corporation of America reported false-positive results using the first commercially available Zika serological IgM test, which is manufactured by InBios International.

As a result, the FDA issued recommendations to physicians using the test not to depend solely on it to diagnose patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.

Oct
19

This webinar will discuss how new quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) tests can accelerate the discovery and development of much-needed anti-malarial drugs and vaccines.